Literature DB >> 21164359

Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?

Giannoula Lakka Klement, Barton A Kamen.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21164359      PMCID： PMC5478384          DOI： 10.1097/MPH.0b013e3182024918

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


× No keyword cloud information.
  34 in total

1.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Docetaxel versus paclitaxel for antiangiogenesis.

Authors:  Angelo Vacca; Domenico Ribatti; Monica Iurlaro; Francesca Merchionne; Beatrice Nico; Roberto Ria; Franco Dammacco
Journal:  J Hematother Stem Cell Res       Date:  2002-02

3.  Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.

Authors:  Nan Soon Wong; Robert A Buckman; Mark Clemons; Shailendra Verma; Susan Dent; Maureen E Trudeau; Kathie Roche; John Ebos; Robert Kerbel; Gerrit E Deboer; Donald J A Sutherland; Urban Emmenegger; Joyce Slingerland; Sandra Gardner; Kathleen I Pritchard
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

4.  A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.

Authors:  Naser Abd El Bary; Tarek Hashem; Hasan Metwally; Ashraf Abd Ghany; Hager Abd El Mageed
Journal:  Hematol Oncol Stem Cell Ther       Date:  2010

5.  UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.

Authors:  Ulrich Herrlinger; Johannes Rieger; Joachim P Steinbach; Thomas Nägele; Johannes Dichgans; Michael Weller
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

6.  Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.

Authors:  Traore Fousseyni; Maimouna Diawara; Eddy Pasquier; Nicolas André
Journal:  J Pediatr Hematol Oncol       Date:  2011-01       Impact factor: 1.289

7.  Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial.

Authors:  M I Koukourakis; C Kourousis; M Kamilaki; S Koukouraki; A Giatromanolaki; S Kakolyris; A Kotsakis; N Androulakis; N Bahlitzanakis; V Georgoulias
Journal:  Eur J Cancer       Date:  1998-05       Impact factor: 9.162

8.  Treatment of non-small-cell lung cancer with prolonged oral etoposide.

Authors:  S Kakolyris; G Samonis; M Koukourakis; I Vlachonicolis; G Chalkiadakis; K Kalbakis; I Souglakos; S Agelaki; P Toloudis; V Georgoulias
Journal:  Am J Clin Oncol       Date:  1998-10       Impact factor: 2.339

9.  Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.

Authors:  Laura Orlando; Anna Cardillo; Raffaella Ghisini; Andrea Rocca; Alessandra Balduzzi; Rosalba Torrisi; Giulia Peruzzotti; Aron Goldhirsch; Elisabetta Pietri; Marco Colleoni
Journal:  BMC Cancer       Date:  2006-09-15       Impact factor: 4.430

10.  Tumour dormancy in breast cancer: an update.

Authors:  Muriel Brackstone; Jason L Townson; Ann F Chambers
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466
View more
  8 in total

Review 1.  Metronomics: towards personalized chemotherapy?

Authors:  Nicolas André; Manon Carré; Eddy Pasquier
Journal:  Nat Rev Clin Oncol       Date:  2014-06-10       Impact factor: 66.675

2.  Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.

Authors:  Eddy Pasquier; Mark W Kieran; Jaroslav Sterba; Yuval Shaked; Sylvain Baruchel; Odile Oberlin; Maria Sanna Kivivuori; Andreas Peyrl; Mamouna Diawarra; Michaela Casanova; Stergios Zacharoulis; Gilles Vassal; Franck Berthold; Arnauld Verschuur; Nicolas André
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

Review 3.  Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.

Authors:  Irina Kareva; David J Waxman; Giannoula Lakka Klement
Journal:  Cancer Lett       Date:  2014-12-23       Impact factor: 8.679

4.  Conceptualizing a tool to optimize therapy based on dynamic heterogeneity.

Authors:  David Liao; Luis Estévez-Salmerón; Thea D Tlsty
Journal:  Phys Biol       Date:  2012-11-29       Impact factor: 2.583

5.  Generalized principles of stochasticity can be used to control dynamic heterogeneity.

Authors:  David Liao; Luis Estévez-Salmerón; Thea D Tlsty
Journal:  Phys Biol       Date:  2012-11-29       Impact factor: 2.583

6.  Pilot study of a pediatric metronomic 4-drug regimen.

Authors:  Nicolas André; Sylvie Abed; Daniel Orbach; Corinne Armari Alla; Laetitia Padovani; Eddy Pasquier; Jean Claude Gentet; Arnauld Verschuur
Journal:  Oncotarget       Date:  2011-12

7.  An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.

Authors:  Amar Jyoti; Kyle D Fugit; Pallavi Sethi; Ronald C McGarry; Bradley D Anderson; Meenakshi Upreti
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

8.  Metronomics: Intrinsic Anakoinosis Modulator?

Authors:  André Nicolas; Manon Carré; Eddy Pasquier
Journal:  Front Pharmacol       Date:  2018-06-25       Impact factor: 5.810
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.